Eli Lilly Cuts Q4 Revenue Guidance, Expects Around $5.5 Billion Sales From Weight Loss/Diabetes Drugs, Stock Tanks
Eli Lilly and Co (NYSE: LLY) announced that it expects 2024 full-year worldwide revenue to be approximately $45.0 billion, representing a 32% growth compared to the previous year versus the consensus of $45.
Zepbound, Lilly and Mounjaro
24/7 Wall St. on MSN1d
Down 23%, Is This Dividend Giant a Buy After GLP-1 Sales Miss?Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...
Eli Lilly shares fell after the drugmaker warned that sales of its hot diabetes and anti-obesity drugs are growing more slowly than expected. Lilly now expects fourth-quarter sales of $3.5 billion for ...
Baltimore's school board joined districts across the country in suing drug makers over the skyrocketing costs of diabetes ...
The Baltimore City Board of School Commissioners is suing Eli Lilly and Co., UnitedHealth Group, CVS and several other drug ...
Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...
The company said it overestimated demand of its obesity and diabetes drugs in the fourth quarter, but projected a further ...
for both drugs, indicating strong market acceptance and potential for continued revenue growth. The success of these GLP-1 receptor agonists has positioned Eli Lilly as a leader in the ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback